These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Developing therapeutics for the diseases of protein misfolding. May BC; Govaerts C; Cohen FE Neurology; 2006 Jan; 66(2 Suppl 1):S118-22. PubMed ID: 16432139 [TBL] [Abstract][Full Text] [Related]
4. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Soto C; Estrada L; Castilla J Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510 [TBL] [Abstract][Full Text] [Related]
5. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Forman MS; Trojanowski JQ; Lee VM Nat Med; 2004 Oct; 10(10):1055-63. PubMed ID: 15459709 [TBL] [Abstract][Full Text] [Related]
7. Mechanical stress and formation of protein aggregates in neurodegenerative disorders. Hachiya NS; Kozuka Y; Kaneko K Med Hypotheses; 2008; 70(5):1034-7. PubMed ID: 17910993 [TBL] [Abstract][Full Text] [Related]
8. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Gaggelli E; Kozlowski H; Valensin D; Valensin G Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441 [No Abstract] [Full Text] [Related]
9. Branched chain mechanism of polymerization and ultrastructure of prion protein amyloid fibrils. Baskakov IV FEBS J; 2007 Aug; 274(15):3756-65. PubMed ID: 17617227 [TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Rochet JC Expert Rev Mol Med; 2007 Jun; 9(17):1-34. PubMed ID: 17597554 [TBL] [Abstract][Full Text] [Related]
11. Amyloid peptides and proteins in review. Harrison RS; Sharpe PC; Singh Y; Fairlie DP Rev Physiol Biochem Pharmacol; 2007; 159():1-77. PubMed ID: 17846922 [TBL] [Abstract][Full Text] [Related]
12. [Conformationally altered proteins cause neurodegenerative diseases]. Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392 [TBL] [Abstract][Full Text] [Related]
13. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. Guest WC; Silverman JM; Pokrishevsky E; O'Neill MA; Grad LI; Cashman NR J Toxicol Environ Health A; 2011; 74(22-24):1433-59. PubMed ID: 22043906 [TBL] [Abstract][Full Text] [Related]
14. [Prion proteins: folding and aggregation properties]. Bousset L; Melki R Med Sci (Paris); 2005; 21(6-7):634-40. PubMed ID: 15985207 [TBL] [Abstract][Full Text] [Related]
15. The reconstitution of mammalian prion infectivity de novo. Baskakov IV FEBS J; 2007 Feb; 274(3):576-87. PubMed ID: 17288547 [TBL] [Abstract][Full Text] [Related]
17. A new route to non invasive diagnosis in neurodegenerative diseases? Carletti T; Fanelli D; Guarino A Neurosci Lett; 2006 Feb; 394(3):252-5. PubMed ID: 16303251 [TBL] [Abstract][Full Text] [Related]
18. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Lansbury PT; Lashuel HA Nature; 2006 Oct; 443(7113):774-9. PubMed ID: 17051203 [TBL] [Abstract][Full Text] [Related]
19. Protein aggregation and prionopathies. Renner M; Melki R Pathol Biol (Paris); 2014 Jun; 62(3):162-8. PubMed ID: 24698014 [TBL] [Abstract][Full Text] [Related]
20. [Approaches from genetical analyses on human diseases: neurodegenerative diseases]. Kakizuka A Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):792-7. PubMed ID: 10771635 [No Abstract] [Full Text] [Related] [Next] [New Search]